Mirikizumab provides sustained long-term efficacy up to 4 years of treatment for ulcerative colitis: final results from the lucent-3 open-label extension study

B E Sands, D B Clemow, G D’Haens, S Vermeire, P Irving, T Kobayashi, L Peyrin-Biroulet, K Samaan, A Gaur, J Paulissen, S Folian, R Arora, N Paquette, R Moses, A Dignass · Zeitschrift für Gastroenterologie · 2026 · Heft 08 · S. e312-e314